Medical professionals should really contemplate whether their people with fundamental NAION danger variables might be adversely impacted by use of PDE5 inhibitors. Individuals who have previously skilled NAION are at increased danger of NAION recurrence. Consequently, PDE5 inhibitors, such as LEVITRA, need to be used with caution in these patients